A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.
Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.
advertisement
Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Listen: Biogen's messy board & Laronde's data problem
Next article： Hollywood unions extend contract negotiations for actors
Next article： Hollywood unions extend contract negotiations for actors
